ThinPrep labeling enhanced
This article was originally published in The Gray Sheet
FDA clears liquid-based Pap test for the detection of glandular lesions, Cytyc announces Sept. 8. Glandular lesions are linked to the only endocervical form of cancer that is increasing in the U.S., particularly among women under 35, according to company statistics. ThinPrep's approved labeling cites multiple peer-reviewed publications indicating the superior sensitivity and specificity of the test in diagnosing glandular disease versus the conventional Pap smear. ThinPrep is now the only cervical cancer technology to carry this label, Cytyc says...
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.